What is NDC 0074-1040?

0074-1040 is the product NDC for Survanta (beractant), Beractant 25 mg/mL suspension, listed with the FDA by AbbVie Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.

AbbVie Inc., NDC labeler code 0074. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Survanta?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Survanta NDC 0074-1040 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)0074-1040Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00074-1040Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0074-1040-04	00074104004	1 VIAL, SINGLE-USE in 1 CARTON (0074-1040-04) / 4 mL in 1 VIAL, SINGLE-USEMarketed from Jul 1, 1991
0074-1040-08	00074104008	1 VIAL, SINGLE-USE in 1 CARTON (0074-1040-08) / 8 mL in 1 VIAL, SINGLE-USEMarketed from Jul 1, 1991

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Survanta
Generic name (nonproprietary): beractant
Active ingredients: Beractant — 25 mg/mL
Dosage form: Suspension
Route: Endotracheal
Labeler: AbbVie Inc.NDC labeler code 0074
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 020032
Marketing start: Jul 1, 1991
Listing expires: Dec 31, 2026
Identifiers: Product ID 0074-1040_6ff1e6a7-1578-4e78-b34f-eb204b23554cSPL ID 6ff1e6a7-1578-4e78-b34f-eb204b23554cSPL set ID 7ef9e3a5-fc39-4ae1-0dad-6b47a1684635RxCUI 259034, 861715UNII S866O45PIG

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N400074104004 followed by a unit qualifier and the quantity

Package 00074-1040-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 15, 2020.

Indications (excerpt from the label)

INDICATIONS AND USAGE SURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0074-1040

What is NDC 0074-1040?: 0074-1040 is the product NDC for Survanta (beractant), Beractant 25 mg/mL suspension, listed with the FDA by AbbVie Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Survanta (Beractant).
What is the active ingredient?: Beractant.
Who is the labeler?: AbbVie Inc., NDC labeler code 0074. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Survanta?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Survanta (Beractant) NDC 0074-1040